sitamaquine
Phase 2Small molecule
GSKsitamaquine is one of 41 small molecule programs targeting Pneumonia. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
547 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Prevacid
TakedaPreclinical
Neutrexin
WWest Japan Thoracic Oncology Group
Preclinical
Zantac 150
CChattem
Preclinical
sitamaquine
GSKPhase 2
Pepcid
KKenvue Brands
Preclinical
Aciphex
Akero TherapeuticsPreclinical
Mucinex
AAultman Health Foundation
Preclinical
Tagamet
DDT MedTech, LLC
Preclinical
Piperacillin/tazobactam
PfizerPreclinical
PCV13
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tolerance1 trial
Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000740·44 enrolled
Visceral Leishmaniasis1 trial
Pneumonia1 trial
A Study of WR 6026 in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000863·45 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sitamaquine. EMBL-EBI & Wellcome Sanger Institute.
- [4]